Related Experiment Video

Updated: Feb 1, 2026

Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury
07:23

Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury

Published on: March 7, 2022

7.2K

microRNA-183 improve myocardial damager via NF-kb pathway: In vitro and in vivo study

Jie Xing1, Ting Xie1, Wei Tan1

  • 1Department of Cardiac surgery, Hainan General Hospital, Haikou, Hainan, China.

Journal of Cellular Biochemistry
|December 15, 2018
PubMed
Abstract

Insights

MicroRNA-183 (miRNA-183) significantly reduces myocardial damage by suppressing cell apoptosis and improving cardiac pathology. This protective effect is mediated through the nuclear factor-kappa B (NF-κb) pathway.

Area of Science:

  • Cardiovascular Biology
  • Molecular Medicine
  • Biochemistry

Background:

  • Myocardial damage is a significant contributor to cardiovascular disease.
  • MicroRNAs play crucial roles in regulating cellular processes, including apoptosis and inflammation.
  • Understanding the specific roles of microRNAs in myocardial injury is essential for developing targeted therapies.

Purpose of the Study:

  • To investigate the therapeutic effects of microRNA-183 (miRNA-183) on myocardial damage.
  • To elucidate the underlying molecular mechanisms, particularly the involvement of the NF-κb pathway.

Main Methods:

  • In vitro studies using H9C2 cells to assess apoptosis and protein expression via flow cytometry and Western blot.
  • In vivo studies in a rat model of myocardial infarction to evaluate pathology, infarct size, apoptosis, and protein levels using histological and molecular techniques.

Main Results:

  • miRNA-183 treatment significantly suppressed cell apoptosis in both in vitro and in vivo models.
  • Histological analysis showed improved cardiac pathology and reduced infarct size in the miRNA-183 group.
  • Key protein expressions, including nuclear factor-kappa B (NF-κb), caspase-3, Bax, and Bcl-2, were significantly altered by miRNA-183.

Conclusions:

  • MicroRNA-183 demonstrates a protective effect against myocardial damage.
  • The beneficial effects of miRNA-183 are achieved by inhibiting cell apoptosis and improving cardiac tissue integrity.
  • The NF-κb pathway is identified as a key mediator of miRNA-183's cardioprotective actions.
Keywords:
BaxBcl-2NF-κbcaspase-3miRNA-183myocardial damager

More Related Videos

Stimulation of Cytoplasmic DNA Sensing Pathways In Vitro and In Vivo11:44

Stimulation of Cytoplasmic DNA Sensing Pathways In Vitro and In Vivo

Published on: September 18, 2014

9.3K
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

8.7K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.2K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.0K
Equivalence: In Vitro and In Vivo Bioequivalence01:17

Equivalence: In Vitro and In Vivo Bioequivalence

Body:Bioequivalence studies are crucial in evaluating whether new drugs can match an approved one regarding pharmacological effects and clinical performance. These studies test if drugs, despite different dosage forms, share identical plasma concentration-time profiles. Three types of equivalence are central to these studies: chemical, pharmaceutical, and therapeutic. Chemical equivalence indicates that two or more drug products contain identical active ingredients in equal amounts.
224
C4 Pathway and CAM01:27

C4 Pathway and CAM

Most plants use the C3 pathway for carbon fixation. However, some plants, such as sugar cane, corn, and cacti that grow in hot conditions, use alternative pathways to fix carbon and conserve energy loss due to photorespiration. Photorespiration is the process that occurs when the oxygen concentration is high. Under such conditions, the rubisco enzyme in the Calvin cycle binds O2 instead of CO2, which halts photosynthesis and consumes energy.
C4 Pathway
The C4 pathway is used by plants such as...
49.2K
Methods for Studying Drug Absorption: In vitro01:16

Methods for Studying Drug Absorption: In vitro

In vitro experiments are crucial for understanding the transport and absorption of drugs through biological materials. These studies employ varied methods such as the diffusion cell method, the everted sac technique, and the everted ring technique.
The diffusion cell method uses a two-compartment cell, including a donor compartment with the drug solution, which simulates the environment where the drug is applied, and a receptor compartment with a buffer solution, which simulates the environment...
609
Drug Product Performance: In Vitro–In Vivo Correlation01:20

Drug Product Performance: In Vitro–In Vivo Correlation

In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while...
276